Effective of treatment of patients with severe psoriasis by Netakimab
Psoriasis is a chronic immune-mediated skin disease. The severity of the disease depends on a number of factors, such as the extent and location of skin lesions, the intensity of itching, and the presence of comorbidities such as psoriatic arthritis. Moderate to severe psoriasis is diagnosed if the skin lesion is diffuse, covers more than 10 % of the body surface and/or involves sensitive areas such as the face, genitals, folds or nails, or has a strong impact on the quality of life of patients, and occurs in about 15 % of cases. In recent years, improved understanding of the pathophysiology of psoriasis has led to the development of a large number of effective and safe therapies, including biologics, that are indicated for moderate to severe psoriasis. Various classes of biologics are already approved and in use, including TNF-α inhibitors (etanercept, infliximab, adalimumab, and certolizumab pegol), IL-12/23 (ustekinumab), IL-17 (secukinumab, ixekizumab, brodalumab) and IL-23 (guselcumab, risankizumab, tildrakizumab). The purpose of the study: is to evaluate the efficacy and safety of the newest biological drug for the treatment of chronic plaque psoriasis, the IL-17 inhibitor netakimab. Material and methods: the main group consisted of 22 patients suffering from severe forms of psoriasis, who were treated at the European Medical Center and Branch N8 of the N.N. Burdenko GVKG of the RF Ministry of Defense for the period 2019-2022. For statistical analysis, M, σ, ±m, Chi-square were calculated. Results. All patients of the study group received therapy with Netakimab (Efleira) at a dose of 120 mg in the form of two s / c injections of 1 ml of the drug at a concentration of 60 mg / ml. Once a week for weeks 0, 1 and 2, then once every 4 weeks. The total follow-up time was 36 months. Almost complete cleansing of the skin (PASI75) was recorded in all patients of the study group 9 months after the start of therapy, the skin process remained in a stable state throughout the observation period. In all patients of the control group, complete cleansing of the skin did not occur. Achievement of PASI75 was recorded in 67 % of patients after 15 months of follow-up. Not all patients complied with all standard recommendations and periodically interrupted the therapy regimen. Resume. Netakimab is an effective drug with a favorable safety profile and low immunogenicity over three years of treatment. 96 % of patients achieved PASI75 within 6 months from the start of systemic therapy with netakimab, compared with the control group, in which PASI75 after 6 months of treatment reached 40 % of patients